The DOI matches its Crossref record; 353 of the 353 references it cites were found in a registry or an index.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Open accessAbstract
T cells can enter an irreversible dysfunctional state that cannot be rescued by PD-1/PD-L1 blockade. In most advanced cancers, except Hodgkin lymphoma (which has high PD-L1/L2 expression) and melanoma (which has high tumor mutational burden), the objective response rate with anti-PD-1/PD-L1 monotherapy is only ~20%, and immune-related toxicities and hyperprogression can occur in a small subset of patients during PD-1/PD-L1 blockade therapy. The lack of efficacy in up to 80% of patients was not necessarily associated with negative PD-1 and PD-L1 expression, suggesting that the roles of PD-1/PD-L1 in immune suppression and the mechanisms of action of antibodies remain to be better defined. In addition, important immune regulatory mechanisms within or outside of the PD-1/PD-L1 network need to be discovered and targeted to increase the response rate and to reduce the toxicities of immune checkpoint blockade therapies. This paper reviews the major functional and clinical studies of PD-1/PD-L1, including those with discrepancies in the pathologic and biomarker role of PD-1 and PD-L1 and the effectiveness of PD-1/PD-L1 blockade. The goal is to improve understanding of the efficacy of PD-1/PD-L1 blockade immunotherapy, as well as enhance the development of therapeutic strategies to overcome the resistance mechanisms and unleash the antitumor immune response to combat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–353 of 353
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Totpal, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365
Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
Guinan, E., Gribben, J., Boussiotis, V., Freeman, G., & Nadler, L. (1994) · Blood · doi:10.1182/blood.v84.10.3261.3261 · Cited by 358
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30126-7 · Cited by 334
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Andorsky, D. J., Yamada, R. E., Said, J., Pinkus, G. S., Betting, D. J., & Timmerman, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2660 · Cited by 328
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 323
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection
Scott-Browne, J. P., López-Moyado, I. F., Trifari, S., Wong, V., Chavez, L., Rao, A., & Pereira, R. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.028 · Cited by 313
Exhaustion-associated regulatory regions in CD8 + tumor-infiltrating T cells
Mognol, G. P., Spreafico, R., Wong, V., Scott-Browne, J. P., Togher, S., Hoffmann, A., Hogan, P. G., Rao, A., & Trifari, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620498114 · Cited by 310
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Self-citationTemporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Gabrielson, A., Wu, Y., Wang, H., Jiang, J., Kallakury, B., Gatalica, Z., Reddy, S., Kleiner, D., Fishbein, T., Johnson, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0110 · Cited by 299
Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 299
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Carreras, J., Lopez-Guillermo, A., Roncador, G., Villamor, N., Colomo, L., Martinez, A., Hamoudi, R., Howat, W. J., Montserrat, E., & Campo, E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0513 · Cited by 296
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287 · cited 1×
“The transcription factors and pathways positively regulating PD-1 expression include BLIMP-1 (although conflicting results were also reported) (313, 314), IFN-α–IRF9 (315), TGFβ–SMAD3 (316), NFATc1 (317), STAT3/4/NFATc1/CTCF (318), the Notch signaling pathway (319), FOXP1 (320), c-FOS (321), STAT1/2 (322), and NF-κB (…”
BackgroundBennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280
Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93397 · Cited by 280
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H.-R., Pyle, K. J., Hipkiss, E., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272
Tewalt, E. F., Cohen, J. N., Rouhani, S. J., Guidi, C. J., Qiao, H., Fahl, S. P., Conaway, M. R., Bender, T. P., Tung, K. S., Vella, A. T., et al. (2012) · Blood · doi:10.1182/blood-2012-04-427013 · Cited by 270
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
Schurich, A., Pallett, L. J., Jajbhay, D., Wijngaarden, J., Otano, I., Gill, U. S., Hansi, N., Kennedy, P. T., Nastouli, E., Gilson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.078 · Cited by 256
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 255
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 253
Krempski, J., Karyampudi, L., Behrens, M. D., Erskine, C. L., Hartmann, L., Dong, H., Goode, E. L., Kalli, K. R., & Knutson, K. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100274 · Cited by 251
Duraiswamy, J., Ibegbu, C. C., Masopust, D., Miller, J. D., Araki, K., Doho, G. H., Tata, P., Gupta, S., Zilliox, M. J., Nakaya, H. I., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001783 · Cited by 246
PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues
Keir, M. E., Freeman, G. J., & Sharpe, A. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5064 · Cited by 245
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K., Pardoll, D. M., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-11-060087 · Cited by 239
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237 · cited 6×
“One preclinical study showed that the antitumor effect of anti-PD-1 therapy required the presence of PD-1loCD8+ T cells before treatment and decreased frequencies of tumor-infiltrating PD-1+CD8+ T cells below a threshold after the anti-PD-1 therapy (24).”
BackgroundResultInfluentialHonda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
Inozume, T., Hanada, K.-I., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 233
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Wang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
Interaction of human PD-L1 and B7-1
Butte, M. J., Peña-Cruz, V., Kim, M.-J., Freeman, G. J., & Sharpe, A. H. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.05.014 · Cited by 228
B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function
Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218
Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., Zhao, H., Liu, C., Yu, J., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0496 · Cited by 218
Penaloza-MacMaster, P., Kamphorst, A. O., Wieland, A., Araki, K., Iyer, S. S., West, E. E., O’Mara, L., Yang, S., Konieczny, B. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132577 · Cited by 213
Williams, J. B., Horton, B. L., Zheng, Y., Duan, Y., Powell, J. D., & Gajewski, T. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160485 · Cited by 210
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Differential binding properties of B7-H1 and B7-DC to programmed death-1
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D. M., Chen, L., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01257-9 · Cited by 209
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
Frebel, H., Nindl, V., Schuepbach, R. A., Braunschweiler, T., Richter, K., Vogel, J., Wagner, C. A., Loffing-Cueni, D., Kurrer, M., Ludewig, B., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121015 · Cited by 209
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208 · cited 1×
“Furthermore, several studies showed that PD-1 and PD-L1, but not PD-L2, induce T cell tolerance and apoptosis, preventing auto/alloimmune responses (16, 67, 97, 116, 127, 128).”
ResultWebb, J. R., Milne, K., & Nelson, B. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0239 · Cited by 202
The Roles of IL-12 in Providing a Third Signal for Clonal Expansion of Naive CD8 T Cells
Valenzuela, J., Schmidt, C., & Mescher, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6842 · Cited by 193
Nishimura, H., Honjo, T., & Minato, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.891 · Cited by 192
Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737461 · Cited by 190
Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo
Sandner, S. E., Clarkson, M. R., Salama, A. D., Sanchez-Fueyo, A., Domenig, C., Habicht, A., Najafian, N., Yagita, H., Azuma, M., Turka, L. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3408 · Cited by 189
Lucas, J. A., Menke, J., Rabacal, W. A., Schoen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 189
The New B7s: Playing a Pivotal Role in Tumor Immunity
Flies, D. B., & Chen, L. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802e085a · Cited by 189
Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., Connelly, C. F., Pak, C. J., Carey, C. D., Daadi, S. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0201 · Cited by 189
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Goldberg, M. V., Maris, C. H., Hipkiss, E. L., Flies, A. S., Zhen, L., Tuder, R. M., Grosso, J. F., Harris, T. J., Getnet, D., Whartenby, K. A., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062422 · Cited by 187
Patsoukis, N., Li, L., Sari, D., Petkova, V., & Boussiotis, V. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-13 · Cited by 187
Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., Blank, C., Cranmer, L. D., Robert, C., Pavlick, A. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.022 · Cited by 187
Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver
Isogawa, M., Furuichi, Y., & Chisari, F. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.005 · Cited by 186 · cited 4×
“An in vivo kinetics study of T cell response to hepatitis B virus infection also showed that after intrahepatic antigen recognition, CD8+ T cells first showed rapid induction and decline of IFN-γ-producing capacity, followed by delayed T cell expansion and an increase in cytolytic activity, and the functional oscillat…”
BackgroundInfluentialAger, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 180
Reiley, W. W., Shafiani, S., Wittmer, S. T., Tucker-Heard, G., Moon, J. J., Jenkins, M. K., Urdahl, K. B., Winslow, G. M., & Woodland, D. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006298107 · Cited by 178
Keir, M. E., Latchman, Y. E., Freeman, G. J., & Sharpe, A. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7372 · Cited by 172
Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation
Kanai, T., Totsuka, T., Uraushihara, K., Makita, S., Nakamura, T., Koganei, K., Fukushima, T., Akiba, H., Yagita, H., Okumura, K., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4156 · Cited by 170
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Lamichhane, P., Karyampudi, L., Shreeder, B., Krempski, J., Bahr, D., Daum, J., Kalli, K. R., Goode, E. L., Block, M. S., Cannon, M. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0740 · Cited by 170
Ito, T., Ueno, T., Clarkson, M. R., Yuan, X., Jurewicz, M. M., Yagita∥, H., Azuma, M., Sharpe, A. H., Auchincloss, H., Sayegh, M. H., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6648 · Cited by 167
Austin, J. W., Lu, P., Majumder, P., Ahmed, R., & Boss, J. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302750 · Cited by 167
NF-κB Regulates PD-1 Expression in Macrophages
Bally, A. P. R., Lu, P., Tang, Y., Austin, J. W., Scharer, C. D., Ahmed, R., & Boss, J. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402550 · Cited by 166
Saha, A., Aoyama, K., Taylor, P. A., Koehn, B. H., Veenstra, R. G., Panoskaltsis-Mortari, A., Munn, D. H., Murphy, W. J., Azuma, M., Yagita, H., et al. (2013) · Blood · doi:10.1182/blood-2013-05-500801 · Cited by 166
Lu, P., Youngblood, B., Austin, J. W., Mohammed, A. U. R., Butler, R., Ahmed, R., & Boss, J. M. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130208 · Cited by 165
Siska, P. J., van der Windt, G. J. W., Kishton, R. J., Cohen, S., Eisner, W., MacIver, N. J., Kater, A. P., Weinberg, J. B., & Rathmell, J. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502464 · Cited by 163
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection
Subudhi, S. K., Zhou, P., Yerian, L. M., Chin, R. K., Lo, J. C., Anders, R. A., Sun, Y., Chen, L., Wang, Y., Alegre, M.-L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19210 · Cited by 161
B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
Liu, X., Gao, J. X., Wen, J., Yin, L., Li, O., Zuo, T., Gajewski, T. F., Fu, Y., Zheng, P., & Liu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022089 · Cited by 161
Moreno, B. H., Zaretsky, J. M., García-Díaz, Á., Tsoi, J., Parisi, G., Robert, L., Meeth, K. M., Ndoye, A., Bosenberg, M., Weeraratna, A. T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0060 · Cited by 160
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells
Stephen, T. L., Payne, K. K., Chaurio, R. A., Allegrezza, M. J., Zhu, H., Perez-Sanz, J., Perales-Puchalt, A., Nguyen, J. M., Vara-Ailor, A. E., Eruslanov, E. B., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.015 · Cited by 160
Regulation of T cell activation and tolerance by PDL2
Zhang, Y., Chung, Y., Bishop, C., Daugherty, B., Chute, H., Holst, P., Kurahara, C., Lott, F., Sun, N., Welcher, A. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601347103 · Cited by 159
Shin, T., Kennedy, G., Gorski, K., Tsuchiya, H., Koseki, H., Azuma, M., Yagita, H., Chen, L., Powell, J., Pardoll, D., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030242 · Cited by 159
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & Doeberitz, M. V. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 156
Martín‐Orozco, N., Wang, Y.-H., Yagita∥, H., & Dong, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8291 · Cited by 156
Yamazaki, T., Akiba, H., Koyanagi, A., Azuma, M., Yagita∥, H., & Okumura, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1586 · Cited by 153
Yang, Z. Z., Grote, D. M., Ziesmer, S. C., Xiu, B., Novak, A. J., & Ansell, S. M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.1 · Cited by 152
Yamamoto, R., Nishikori, M., Tashima, M., Sakai, T., Ichinohe, T., Takaori‐Kondo, A., Ohmori, K., & Uchiyama, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01302.x · Cited by 147
Notch signaling regulates PD‐1 expression during CD8 + T‐cell activation
Mathieu, M., Cotta‐Grand, N., Daudelin, J., Thébault, P., & Labrecque, N. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.53 · Cited by 146
Nishino, M., Giobbie‐Hurder, A., Manos, M. P., Bailey, N., Buchbinder, E. I., Ott, P. A., Ramaiya, N. H., & Hodi, F. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0114 · Cited by 146
Fernández-Poma, S. M., Salas‐Benito, D., Lozano, T., Casares, N., Riezu‐Boj, J. I., Mancheño, U., Elizalde, E., Alignani, D., Zubeldia, N., Otano, I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0236 · Cited by 144
Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J., Tokunaga, T., Nakao, T., Kashihara, H., Takasu, C., Iwata, T., & Shimada, M. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0519-7 · Cited by 142
Hao, Y., Chapuy, B., Monti, S., Sun, H. H., Rodig, S. J., & Shipp, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3007 · Cited by 141
Saudemont, A., Jouy, N., Hétuin, D., & Quesnel, B. (2004) · Blood · doi:10.1182/blood-2004-09-3458 · Cited by 139
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Kleinovink, J. W., Marijt, K. A., Schoonderwoerd, M. J. A., van Hall, T., OSSENDORP, F. A., & Fransen, M. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1294299 · Cited by 136
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 133
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 133
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Ahrends, T., Bąbała, N., Xiao, Y., Yagita∥, H., van Eenennaam, H., & Borst, J. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3130 · Cited by 131
Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism
Tkachev, V., Goodell, S., Opipari, A. W., Hao, L.-Y., Franchi, L., Glick, G. D., Ferrara, J. L. M., & Byersdorfer, C. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402180 · Cited by 130
Vetsika, E., Koinis, F., Gioulbasani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D., Georgoulias, V., & Kotsakis, A. P. (2014) · Journal of Immunology Research · doi:10.1155/2014/659294 · Cited by 128
Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators
Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 122
Anti-PD-L1 peptide improves survival in sepsis
Shindo, Y., McDonough, J. S., Chang, K. C., Ramachandra, M., Sasikumar, P. G., & Hotchkiss, R. S. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.08.099 · Cited by 120
Smeltzer, J. P., Jones, J. M., Ziesmer, S. C., Grote, D. M., Xiu, B., Ristow, K. M., Yang, Z. Z., Nowakowski, G. S., Feldman, A. L., Cerhan, J. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2367 · Cited by 119
PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB
Karyampudi, L., Lamichhane, P., Krempski, J. W., Kalli, K. R., Behrens, M. D., Vargas, D. M., Hartmann, L. C., Janco, J. M. T., Dong, H., Hedin, K. E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0748 · Cited by 119
Takeda, Y., Kataoka, K., Yamagishi, J., Ogawa, S., Seya, T., & Matsumoto, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.015 · Cited by 119
Nijland, M., Veenstra, R. N., Visser, L., Xu, C., Kushekhar, K., Imhoff, G. W. V., Kluin, P. M., van den Berg, A., & Diepstra, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295202 · Cited by 115
Ma, S.-D., Xu, X., Jones, R., Delecluse, H., Zumwalde, N. A., Sharma, A., Gumperz, J. E., & Kenney, S. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005642 · Cited by 112
Cho, H.-Y., Lee, S.-W., Seo, S., Choi, I., Choi, I., & Lee, S.-W. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.08.003 · Cited by 111
Matta, B. M., Raimondi, G., Rosborough, B. R., Sumpter, T. L., & Thomson, A. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103382 · Cited by 109
Dorfman, D. M., Schultze, J. L., Shahsafaei, A., Michalak, S., Gribben, J. G., Freeman, G. J., Pinkus, G. S., & Nadler, L. M. (1997) · Blood · doi:10.1182/blood.v90.11.4297 · Cited by 106
Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas
Muenst, S. E., Hoeller, S., Willi, N., Dirnhofer, S., & Tzankov, A. (2010) · Disease Markers · doi:10.1155/2010/404069 · Cited by 106
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells
Ni, X., Song, Q., Cassady, K. M., Deng, R., Jin, H., Zhang, M., Dong, H., Forman, S. J., Martin, P. J., Chen, Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91138 · Cited by 104
Self-citationPyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
Watanabe, R., Shirai, T., Namkoong, H., Zhang, H., Berry, G. J., Wallis, B. B., Schaefgen, B., Harrison, D. G., Tremmel, J. A., Giacomini, J. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92167 · Cited by 103
Munro, J. M., Freedman, A. S., Aster, J. C., Gribben, J. G., Nc, L., Rhynhart, K., Banchereau, J., & Nadler, L. M. (1994) · Blood · doi:10.1182/blood.v83.3.793.793 · Cited by 99
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., & Ahmed, R. (2016) · Journal of Virology · doi:10.1128/jvi.00798-16 · Cited by 99
Kotsakis, A. P., Koinis, F., Katsarou, A., Gioulbasani, M., Aggouraki, D., Kentepozidis, N. K., Georgoulias, V., & Vetsika, E. (2016) · Scientific Reports · doi:10.1038/srep39247 · Cited by 99
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Saha, A., O’Connor, R. S., Thangavelu, G., Lovitch, S. B., Dandamudi, D. B., Wilson, C. B., Vincent, B. G., Tkachev, V., Pawlicki, J. M., Furlan, S. N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85796 · Cited by 98
Pauken, K. E., Jenkins, M. K., Azuma, M., & Fife, B. T. (2013) · Diabetes · doi:10.2337/db12-1475 · Cited by 95
Nishino, M., Dahlberg, S. E., Adeni, A. E., Lydon, C., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1434 · Cited by 91
Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach
Paulsen, E., Kilvaer, T. K., Rakaee, M., Al‐Saad, S., Hald, S. M., Andersen, S., Richardsen, E. H., Ness, N., Busund, L., Bremnes, R. M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.009 · Cited by 90
B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
Pulko, V., Harris, K. J., Liu, X., Gibbons, R., Harrington, S. M., Krco, C. J., Kwon, E. D., & Dong, H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003976 · Cited by 86
Cheng, X., Dai, H., Ni, W., Moore, Y., Vankayalapati, R., & Dai, Z. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a75633 · Cited by 84
Zelinskyy, G., Myers, L. M., Dietze, K. K., Sutter, K., Roggendorf, M., Liu, J., Lu, M., Kraft, A. R. M., Teichgräber, V., Hasenkrug, K. J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101612 · Cited by 82
Buchan, S. L., Manzo, T., Flutter, B. R., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., Carpenter, B., Bennett, C. L., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401644 · Cited by 81
Microanatomical localization of PD-1 in human tonsils
Iwai, Y., Okazaki, T., Nishimura, H., Koyanagi, A., Yagita∥, H., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00088-3 · Cited by 77
Cai, G., Karni, A., de Oliveira, E. M. L., Weiner, H. L., Hafler, D. A., & Freeman, G. J. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.09.004 · Cited by 77
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
Dronca, R. S., Liu, X., Harrington, S. M., Chen, L., Cao, S., Kottschade, L. A., McWilliams, R. R., Block, M. S., Nevala, W. K., Thompson, M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86014 · Cited by 77
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 77
B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation
Talay, O., Shen, C.-H., Chen, L., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813367106 · Cited by 76
PD-1 expression conditions T cell avidity within an antigen-specific repertoire
Simon, S., Vignard, V., Florenceau, L., Dréno, B., Khammari, A., Lang, F., & Labarrière, N. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1104448 · Cited by 76
Recall Responses by Helpless Memory CD8+ T Cells Are Restricted by the Up-Regulation of PD-1
Fuse, S., Tsai, C.-Y., Molloy, M. J., Allie, S. R., Zhang, W., Yagita∥, H., & Usherwood, E. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802041 · Cited by 75
TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
Boes, M. L., & Meyer‐Wentrup, F. A. G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.027 · Cited by 72
Zhu, L., Kong, Y., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Palmisiano, N. D., Wang, M., Jia, B., Bayerl, M. G., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0486-z · Cited by 72
Deng, R., Cassady, K. M., Li, X., Yao, S., Zhang, M., Racine, J. J., Lin, J. J., Chen, L., & Zeng, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402157 · Cited by 67
Self-citationZhou, Q., Xiao, H., Liu, Y., Peng, Y., Yuan, H., Yagita∥, H., Chandler, P., Munn, D. H., Mellor, A. L., Fu, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001821 · Cited by 67
Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response
Seo, S., Seo, H.-M., Jeong, H.-Y., Choi, I.-W., Park, Y.-M., Yagita∥, H., Chen, L., & Choi, I.-H. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.09.007 · Cited by 62
Bhadra, R., Gigley, J. P., & Khan, I. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102319 · Cited by 62
Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential
Clark, C. A., Gupta, H. B., & Curiel, T. J. (2017) · Autophagy · doi:10.1080/15548627.2017.1280223 · Cited by 59
Canton, D. A., Shirley, S. A., Wright, J. H., Connolly, R. J., Burkart, C., Mukhopadhyay, A., Twitty, C., Qattan, K. E., Campbell, J. S., Le, M. H., et al. (2017) · Immunotherapy · doi:10.2217/imt-2017-0096 · Cited by 59
Pauken, K. E., Nelson, C. E., Martinov, T., Spanier, J. A., Heffernan, J. R., Sahli, N. L., Quarnstrom, C. F., Osum, K. C., Schenkel, J. M., Jenkins, M. K., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402262 · Cited by 52
Leyland, R., Watkins, A., Mulgrew, K. A., Holoweckyj, N., Bamber, L., Tigue, N. J., Offer, E., Andrews, J. L., Li, Y., Mullins, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2000 · Cited by 52
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Friedman, C. F., & Postow, M. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0509-x · Cited by 46
Penaloza‐MacMaster, P., Provine, N. M., Blass, E., & Barouch, D. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403237 · Cited by 45
Kalkavan, H., Sharma, P., Kasper, S., Helfrich, I., Pandyra, A. A., Gassa, A., Virchow, I., Flatz, L., Brandenburg, T., Namineni, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14447 · Cited by 39
First Tissue-Agnostic Drug Approval Issued
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-078 · Cited by 39
Peters, S., Antonia, S. J., Goldberg, S. B., Heymach, J. V., Kim, E. S., Nakagawa, K., Papadimitrakopoulou, V., Mukhopadhyay, P., McIntosh, S., & Rizvi, N. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30300-8 · Cited by 37
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Ahmad, S. M., Martinenaite, E., Hansen, M., Junker, N., Borch, T. H., Met, Ö., Donia, M., Svane, I. M., & Andersen, M. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1202391 · Cited by 36
Abdel‐Magid, A. F. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00148 · Cited by 30
Dakappagari, N. K., Ho, S. N., Gascoyne, R. D., Ranuio, J., Weng, A. P., & Tangri, S. (2011) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20631 · Cited by 29
Three Drugs Approved for Urothelial Carcinoma by FDA
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-071 · Cited by 26
Kollmann, D., Schweiger, T., Schwarz, S., Ignatova, D., Chang, Y., Lewik, G., SCHOPPMANN, S. F., Hoetzenecker, W., Klepetko, W., Guenova, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331194 · Cited by 25
Shim, K. G., Zaidi, S., Thompson, J., Kottke, T., Evgin, L., Rajani, K. R., Schuelke, M. R., Driscoll, C. B., Huff, A. L., Pulido, J. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.023 · Cited by 23
Dronca, R. S., Mansfield, A. S., Park, S. S., & Dong, H. (2016) · Immunotherapy · doi:10.2217/imt-2016-0100 · Cited by 8
Cited by
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
Li, F., Li, C., Cai, X., Xie, Z., Zhou, L., Cheng, B., Zhong, R., Xiong, S., Li, J., Chen, Z., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101134 · Cited by 363
Self-citationCancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Metadata
- Authors
- Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-12-04
- Volume
- 8
- Pages
- 1597-1597
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2772859838
- Cited by
- 288
- References
- 353
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.